Biocon Limited's Q2 FY27 Revenue Rises 2% to ₹4,389 Crore

Biocon Limited reported revenue from operations of ₹4,389 crore for Q2 FY27, up 2% year-on-year, while EBITDA declined 7% to ₹865 crore and the EBITDA margin narrowed to 20%. The results for the quarter ended September 30, 2026 show modest top-line growth alongside lower operating profitability.

What did Biocon report for Q2 FY27?

Biocon reported total revenue of ₹4,423 crore in the September-quarter of FY27, a 1% increase from the year-ago period. Revenue from operations was ₹4,389 crore, representing 2% year-on-year growth, according to the company’s Q2 FY27 investor presentation and related results summaries released on November 4, 2026.

Operating profitability declined during the quarter. EBITDA stood at ₹865 crore, down 7% from a year earlier, while EBITDA margin fell to 20% from 22% in Q2 FY26. The difference between revenue growth and EBITDA movement indicates that the company’s operating cost base or business mix weighed on margin during the reported period.

The supplied material contains differing references to quarterly profit. One summary reported consolidated net profit of ₹567 million, compared with ₹1,328 million a year earlier, while another results summary cited reported net profit of ₹41 crore, down 52% year-on-year. It also stated that net profit before exceptional items was ₹44 crore. The company’s presentation should remain the primary reference for the final reported metric.

How did Biocon communicate its quarterly update?

Biocon hosted its Q2 FY27 earnings conference call on November 4, 2026, covering the quarter ended September 30, 2026. The company submitted its investor presentation and other disclosures to BSE Limited and the National Stock Exchange of India Limited as part of its listed-company disclosure process.

On November 4, Biocon also issued a Regulation 30 disclosure related to the audio and video recording of the earnings call. An event listing separately identifies November 5, 2026 for the recording. These disclosures give investors access to the company’s formal communication around the quarterly results and management discussion.

The source material notes that a full Q2 FY27 earnings-call transcript was not yet available in one listing. Other references label a transcript event dated November 4. Given these differing publication references, the investor presentation and the reported result figures provide the clearest available basis for assessing the quarter.

The company had previously published the Q1 FY27 earnings-call transcript in August 2026. Its earlier disclosure record also includes Q2 FY26 communication in November 2025 and Q4 FY26 call-related disclosures in May 2026, showing a regular pattern of quarterly investor engagement.

Which businesses supported Biocon's quarterly revenue?

Biocon’s reported operating revenue growth was supported by performance across its business lines, although the supplied material provides limited segment-level absolute figures. The biopharmaceuticals business recorded 5% year-on-year growth, while services revenue increased 13% sequentially, according to the earnings-call highlights.

The company operates across biosimilars, generics and services. Its biologics activities serve regulated markets, including India and the United States, with additional exposure to Europe, Asia-Pacific, the Middle East and Africa through subsidiaries and alliance partners. This footprint makes access, product launches and regional commercial execution relevant to its revenue trend.

Earnings-call highlights pointed to an expectation of stronger performance in the second half of FY27, with double-digit biosimilars growth linked to new launches and improved market access. This was presented as management’s outlook rather than a reported Q2 financial outcome. No full-year revenue or profit target is provided in the supplied material.

The services business’s 13% quarter-on-quarter revenue increase offers a positive operational data point, but it does not offset the need to monitor consolidated profitability. For investors, the movement in EBITDA margin remains important because it captures the conversion of revenue into operating earnings across the group.

Why does the margin decline matter for investors?

The 2 percentage-point decline in EBITDA margin matters because revenue grew while EBITDA fell. Biocon generated ₹865 crore of EBITDA on revenue from operations of ₹4,389 crore, resulting in a 20% margin compared with 22% in the corresponding quarter of FY26.

The result illustrates the difference between sales growth and earnings growth. A company can expand revenue through product sales, services or new market access, but lower operating margin can limit the benefit to profitability. The data provided does not specify individual cost items or segment-level margin drivers, so the reasons for the decline should not be inferred beyond the reported figures.

For shareholders, the next relevant disclosures will be the company’s commentary on commercial execution in biosimilars, new product launches, market access and the trajectory of operating margin. The reported outlook for a stronger second half will be assessed against subsequent quarterly revenue and EBITDA disclosures.

The figures also matter for the broader pharmaceutical sector because biosimilars and regulated-market businesses typically require sustained investment in development, manufacturing, approvals and commercial channels. Biocon’s Q2 performance shows that business-line growth can coexist with near-term pressure on consolidated operating profitability.

Conclusion

Biocon delivered modest Q2 FY27 revenue growth, with revenue from operations increasing 2% year-on-year to ₹4,389 crore. However, EBITDA declined 7% to ₹865 crore and the margin contracted to 20%, making profitability the central financial issue in the quarter rather than the top-line increase.

The next key item to watch is Biocon’s execution in the second half of FY27. Management has indicated that biosimilars could deliver double-digit growth through launches and improved market access, while future filings and any published call transcript may provide greater clarity on margins, profit measures and segment performance.